<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535015</url>
  </required_header>
  <id_info>
    <org_study_id>ANA-CTP0002</org_study_id>
    <nct_id>NCT00535015</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Double-Blind, Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of CACS in Patients With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anaborex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anaborex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Betamarc is effective in improving the
      appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Objectives of study could not be met within a reasonable timeframe.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional capacity (strength and endurance), body composition by DXA, inflammation, patient reported outcomes, anti-tumor response rate</measure>
    <time_frame>25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events, ECG, vital signs, clinical laboratory parameters and physical examination</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>Weight Loss</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamarc</intervention_name>
    <description>2 tabs BID</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after
             resection for earlier stage disease is acceptable as long as patients are at least 6
             months from surgery.

          -  Treatment plan includes a platinum-based doublet chemotherapy.

          -  ECOG 0, 1 or 2.

          -  Self-reported loss of body weight or anorexia.

          -  Serum C-reactive protein â‰¥5 mg/L.

          -  Life expectancy of at least 6 months.

          -  Adequate bone marrow, liver and renal function.

          -  Normal serum potassium.

          -  Ability to comply with the study requirements and give written informed consent.

        Exclusion Criteria:

          -  Known physical or functional obstruction of the gastrointestinal tract, malabsorption,
             intractable vomiting, uncontrollable diarrhea, concurrently receiving tube feeding or
             parenteral nutrition, or unable to swallow investigational drug product.

          -  Concomitant therapy with an appetite stimulant.

          -  History of poorly controlled hypertension or congestive heart failure.

          -  Any implanted devices that could interfere with DXA scanning.

          -  Prolongation of QT interval.

          -  History of additional risk factors for torsades de pointe.

          -  Concomitant therapy with beta-adrenergic receptor antagonists (beta-blockers) or ergot
             derivatives.

          -  Females who are breast feeding, pregnant or of child-bearing potential who are not
             using adequate birth control.

          -  Any second malignancy which might confound the interpretation of safety or efficacy
             assessments.

          -  Any condition which increases the patient's risk for participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yung-chuan Sung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cathay General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hsing-jin Eugene Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University Muncipal Wan Fang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Te-chun Hsia</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gee-chen Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yao-kuang Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tzu Chi General Hospital Taipei Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwok-keung Yuen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuen Mun Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Chua</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chung-kong Kwan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Elizabeth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwok-chi Lam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae-ho Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-seok Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hosptial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hoon-kyo Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Vincent's Hospital, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-hyoung Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea, St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Zarina binti Bustam</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdul Razak bin Abdul Muttalif</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pulau Pinang</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Biswa Mohan Biswal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universiti Sains Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wu-chou Su</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-lin Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chunghua Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-yao Tsao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-ta Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital--Chiayi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wen-Tsung Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chi Mei Medical Center Liou-Ying Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edy Suratman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dharmais Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisna Syahruddin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Persahabatan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Ginting</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gatot Subroto Central Army Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Muncipal Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
  </removed_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2007</study_first_submitted>
  <study_first_submitted_qc>September 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>July 19, 2008</last_update_submitted>
  <last_update_submitted_qc>July 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jeff Rudy, Vice President Clinical Operations</name_title>
    <organization>Anaborex, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

